[go: up one dir, main page]

ME02231B - Amido jedinjenja i njihova upotreba kao farmaceutckih proizvoda - Google Patents

Amido jedinjenja i njihova upotreba kao farmaceutckih proizvoda

Info

Publication number
ME02231B
ME02231B MEP-2015-166A MEP16615A ME02231B ME 02231 B ME02231 B ME 02231B ME P16615 A MEP16615 A ME P16615A ME 02231 B ME02231 B ME 02231B
Authority
ME
Montenegro
Prior art keywords
spiro
pyrrolidin
cyclopropyl
carbonyl
pyridin
Prior art date
Application number
MEP-2015-166A
Other languages
English (en)
Inventor
Wenqing Yao
Jincong Zhuo
Meizhong Xu
Colin Zhang
Brian Metcalf
Chunhong He
Ding-Quan Qian
Original Assignee
Lncyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lncyte Holdings Corp filed Critical Lncyte Holdings Corp
Publication of ME02231B publication Critical patent/ME02231B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (42)

1. Jedinjenje koje ima formulu Va ili Vb:ili njihove farmaceutski prihvatljive soli, gde je: prsten B vezana 5 ili 6-očlana aril ili heteroaril grupa; Q1 je O, S, NH, CH2, CO, CS, SO, SO2, OCH2, SCH2, NHCH2, CH2CH2, CH=CH, COCH2, CONH, COO, SOCH2, SONH, SO2CH2 ili SO2NH;Q2 je O, S, NH, CH2, CO, CS, SO, SO2, OCH2, SCH2, NHCH2, CH2CH2, CH=CH, COCH2, CONH, COO, SOCH2, SONH, SO2CH2ili SO2NH;Cy je aril, heteroaril, cikloalkil ili heterocikloalkil, svaki opciono supstituisan pomoću 1, 2, 3, 4 ili 5 –W-X-Y-Z;R1 i R2 zajedno sa C atomom za koji su vezani formiraju 3-, 4-, 5-, 6- ili 7-očlanu cikloalkil grupu ili 3-, 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu, svaka opciono supstituisana pomoću 1, 2 ili 3 R5; R5 je halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-4 haloalkil, aril, cikloalkil, heteroaril, heterocikloalkil, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)Ra, S(O)Rb, S(O)NRcRd, S(O)2Rb ili S(O)2NRcRd;W, W’ i W’’ svaki je, nezavisni, odsutan, C1-6 alkilenil, C2-6 alkinilenil, O, S, NRe, CO, CS, COO, CONRe, OCONRe, SO, SO2, SONRe ili NReCONRf; gde su pomenuti C1-6 alkilenil, C2-6 alkenilenil opciono supstituisani pomoću 1,2 ili 3 halo, OH, C1-4 alkoksi, C1-4 haloalkoksi, amino, C1-4 alkilamino ili C2-8 dialkilamino; X, X’ i X’’ svaki je nezavisno odsutan, C1-8 alkilenil, C2-8 alkenilenil, C2-8 alkinilenil, aril, cikloaril, heteroaril, heterocikloalkil, arilalkil, cikloalkilalkil, heteroarilalkil, heterocikloalkilalkil, arilalkenil, cikloalkilalkenil, heteroarilalkenil, heterocikloalkilalkenil, arilalkinil, cikloalkilalkinil, heteroarilalkinil, heterocikloalkilalkinil, od kojih je svaki opciono supstituisan pomoću jednog ili više halo, CN, NO2, OH, C1-4 alkoksi, C1-4 haloalkoksi, amino, C1-4 alkilamino ili C2-8 dialkilamino;Y, Y’ i Y’’ je svaki nezavisno odsutan, C1-6 alkilenil, C2-6 alkenilenil, C2-6 alkinilenil, O, S, NRe, CO, CS, COO, CONRe, OCONRe, SO, SO2, SONRe ili NReCONRf gde su pomenuti , C1-6 alkilenil, C2-6 alkenilenil, C2-6 alkinilenil opciono supstituisani sa 1, 2 ili 3 halo, OH, C1-4 alkoksi, C1-4 haloalkoksi, amino, C1-4 alkilamino ili C2-8 dialkilamino;Z, Z’ i Z’’ svaki je nezavisno, H, halo, okso, sulfido, CN, NO2, OH, C1-4 alkoksi, C1-4 haloalkoksi, amino, C1-4 alkilamino ili C2-8 dialkilamino, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil, gde su pomenuti C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil opciono supstituisani sa 1, 2 ili 3 halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-4 haloalkil, aril, cikloalkil, heteroaril, heterocikloalkil, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)NRcRd, NRcRd, NRcC(O)Rd, NRcC(O)ORa, S(O)Rb, S(O)NRcRd, S(O)2Rb ili S(O)2NRcRd; gde su dva –W-X-Y-Z vezana za isti atom opciono formirajući 3-20-očlanu cikloalkil ili heterocikloalkil grupu opciono supstituisanu sa 1, 2 ili 3 –W’’-X’’-Y’’-Z’’;gde je –W-X-Y-Z sve osim H;gde je –W‘-X‘-Y‘-Z sve osim H;gde je –W‘‘-X‘‘-Y‘‘-Z sve osim H;Ra je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, (C1-6 alkoksi)-C1-6 alkil, C2-6 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil;Rb je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril ili heterocikloalkil;Rc i Rd je svaki, nezavisno, H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;ili su Rci Rd zajedno vezani za N atom i formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; Re i Rf su nezavisno, H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, arilalkil ili cikloalkilalkil;ili su Re i Rf vezani za N atom i formiraju 4-, 5-, 6- ili 7-očlanu heterocikloalkil grupu; q je 0 ili 1;v je 0, 1 ili 2;r je 0, 1 ili 2;s je 0, 1 ili 2; i suma r i s je 0, 1 ili 2; i gde se“alkenil” odnosi na alkil grupu koja ima jednu ili više ugljenik-ugljenik dvostrukih veza;“alkinil” odnosi na alkil grupu koja ima jednu ili više ugljenik-ugljenik trostrukih veza;“cikloalkil” odnosi na nearomatične ciklične ugljovodonike uključujući ciklične alkil, alkenil i alkinil grupe; i “heterocikloalkil odnosi na nearomatične heterocikle uključujući ciklični alkil, alkenil i alkinil grupe gde je jedan ili više ugljenika koji formiraju prsten zamenjen heteroatomom kao što je O, N ili S atom.
2. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je Cy aril ili heteroaril, opciono je supstituisan sa 1, 2, 3, 4 ili 5 –W-X-Y-Z.
3. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je Cy aril, opciono je supstituisan sa 1, 2, 3, 4 ili 5 –W-X-Y-Z.
4. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je Cy aril, opciono je supstituisan sa 1, 2 ili 3 halo, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil ili sa C1-4 haloalkoksi.
5. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je Cy fenil, opciono je supstituisan sa 1, 2 ili 3 halo, C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil ili sa C1-4 haloalkoksi.
6. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde su R1 i R2 zajedno vezani za C atom, formiraju 3-, 4-, 5-, 6-, ili 7-očlanu cikloalkil grupu.
7. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde su R1 i R2 zajedno vezani za C atom, formiraju ciklopropil grupu.
8. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je –W-X-Y-Z halo, cijano, C1-4 cijanoalkil, nitro, C1-8 alkil, C2-8 alkenil, C1-8 haloalkil, C1-4 alkiltio, C1-4 haloalkiltio, C1-8 alkoksi, C2-8 alkeniloksi, C1-4 haloakloksi, OH, (C1-4 alkoksi)-C1-4 alkil, amino, C1-4 alkilamino, C2-8 dialkilamino, OC(O)NRcRd, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rd, C(O)ORa, C(O)Ra, C(O)NRaNRbRd, S(O)2Rd, SRd, C(O)NRcRd, C(S)NRcRd, ariloksi, heteroariloksi, cikloariloksi, cikloalkeniloksi, heterocikloalkiloksi, arilalkiloksi, heteroarilalkiloksi, cikloalkilalkiloksi, heterocikloalkilalkiloksi, heteroariloksialkil, ariloksialkil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, cikloalkilalkil ili heterocikloalkilalkil; gde je svaki od pomenutih C1-8 alkil, C2-8 alkenil, C1-8 haloalkil, C1-4 alkiltio, C1-4 haloalkiltio, C1-8 alkoksi, ariloksi, heteroariloksi, arilalkiloksi, heteroarilalkiloksi, heteroariloksialkil, ariloksi, heteroariloksi, cikloalkiloksi, cikloalkeniloksi, heterocikloalkiloksi, arilalkiloksi, heteroarilalkiloksi, cikloalkilalkiloksi, heterocikloalkilalkiloksi, heteroariloksialkil, ariloksialkil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, cikloalkilalkil ili je heterocikloalkilalkil opciono supstituisan sa 1, 2 ili 3 halo, cijano, nitro, hidroksil-(C1-6 alkil), aminoalkil, dialkilaminoalkil, C1-4 alkil, C1-4 hal alkil, C1-4 cijanoalkil, C1-4 alkoksi, C1-4 haloalkoksi, OH, ORa, (C1-4 alkoksi)-C1-4 alkil, amino, C1-4 alkilamino, C2-8 dialkilamino, C(O)NRcRd, C(O)ORa, C(O)Ra, (ciklocalkilalkil)-C(O)-, NRcC(O)Rd, NRcC(O)ORa, NRcS(O)2Rd, C(S)NRcRd, S(O)2Rd, SRd, (C1-4 alkil)sulfonil, arilsulfonil, aril su opciono supstituisani sa halo, heteroaril, cikloalkilalkil, cikloalkil ili heterocikloalkilom.
9. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je -W-X-Y-Z halo, cijano, C1-4 cijanoalkil, nitro, C1-8 alkil, C2-8 alkenil, C1-8 haloalkil, C1-10 alkoksi, C1-4 haloalkoksi, OH, C1-8 alkoksialkil, amino, C1-4 alkilamino, C2-8 dialkilamino, OC(O)NRcRd, NRcC(O)Rd, NRcC(O)ORa, ariloksi, heteroariloksi, arilalkiloksi, heteroarilalkiloksi, heteroariloksialkil, ariloksialkil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, cikloalkilalkil ili heterocikloalkilalkil; gde je svaki od pomenutih C1-8 alkil, C2-8 alkenil, C1-8 haloalkil, C1-8 alkoksi, ariloksi, heteroariloksi, arilalkiloksi, heteroarilalkiloksi, heteroariloksialkil, ariloksialkil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, arilalkenil, arilalkinil, heteroarilalkil, heteroarilalkenil, heteroarilalkinil, cikloalkilalkil ili heterocikloalkilalkil opciono supstituisan sa 1, 2 ili 3 halo, cijano, nitro, hidroksil-(C1-6 alkil), aminoalkil, dialkilaminoalkil, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, C1-4 haloalkoksi, OH, C1-8 alkoksialkil, amino, C1-4 alkilamino, C2-8 dialkilamino, C(O)NRcRd, C(O)ORa , NRcC(O)Rd, NRcS(O)2Rd, (C1-4 alkil)sulfonil, arilsulfonil, aril, heteroaril, cikloalkil ili heterocikloalkilom.
10. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so gde je -W-X-Y-Z is halo, cijano, C1-4 cijanoalkil, nitro, C1-4 nitroalkil, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, C1-4 haloalkoksi, OH, (C1-4 alkoksi)-C1-4 alkil, amino, C1-4 alkilamino, C2-8 dialkilamino, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil.
11. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, -W-X-Y-Z je halo, C1-4 alkil ili C1-4 alkoksi.
12. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je: -W’-X’-Y’-Z’ halo, OH, cijano, CHO, COOH, C(O)O-(C1-4 alkil), C(O)-(C1-4 alkil), SO2-(C1-4 alkil), C1-4 alkil, C1-4 alkoksi ili -L-R7, gde je pomenuti C1-4 alkil ili C1-4 alkoksi opciono supstituisan jednim ili više halo, OH, COOH ili C(O)O-(C1-4 alkil); L je odsutan, O, CH2, NHSO2 ili N[C(O)-(C1-4 alkil)]; i R7 je aril ili heteroaril, svaki je opciono supstituisan sa 1, 2 ili 3 halo, OH, cijano, CHO, COOH, C(O)O-(C1-4 alkil), C(O)-(C1-4 alkil), SO2-(C1-4 alkil), SO2-NH(C1-4 alkil), C1-4 alkil, C1-4 alkoksi, C1-4 haloalkil, C1-4 hidroksialkil, aril, heteroaril ili ariloksi.
13. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je -W’-X’-Y’-Z’ halo; C1-4 alkil; C1-4 haloalkil; OH; C1-4 alkoksi; C1-4 haloalkoksi; hidroksialkil; alkoksialkil; aril; heteroaril; aril supstituisan sa halo, C1-4 alkil, C1-4 alkoksi, aril, heteroaril ili ariloksi; ili heteroaril supstituisan sa halo, C1-4 alkil, C1-4 alkoksi, aril ili heteroaril.
14. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde su dva -W’-X’-Y’-Z’ vezana za isti atom i opciono formiraju 3-20-očlani cikloalkil iliheterocikloalkil grupu opciono supstituisanu sa 1, 2 ili 3 -W’’-X’’-Y’’-Z’’.
15. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, gde je -W"-X"-Y"-Z" halo, cijano, C1-4 cijanoalkil, nitro, C1-4 nitroalkil, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, C1-4 haloalkoksi, OH, (C1-4 alkoksi)-C1-4 alkil, amino, C1-4 alkilamino, C2-8 dialkilamino, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil, or heterocikloalkilalkil.
16. Jedinjenje iz zahteva 1 ili njegova farmaceutski prihvatljiva so, koje ima formulu VI: gde je svaki Q3 i Q4,nezavisno, CH ili N.
17. Jedinjenje iz zahteva 16 ili njegove farmaceutski prihvatljive soli, imaju formulu VII:
18. Jedinjenje iz zahteva 16 ili njegove farmaceutski prihvatljive soli, imaju formulu Formula VIII:
19. Jedinjenje iz zahteva 1 izabrano od:1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-2,3-dihidrospiro[inden-1,4’-piperidin];1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-1-metilspiro[indol-3,4’-piperidin]-2(1H)-on;terc-butil 1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[indol-3,4’-piperidin]-1(2H)-karboksilat;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-2,3-dihidro-1H-spiro[izokinolin-4,4’-piperidin];terc-butil 1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-1H-spiro[izokinolin-4,4’-piperidin]-2(3H)-karboksilat;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-1,3-dihidrospiro[inden-2,4’-piperidin];1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[hromen-2,4’-piperidin];1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,4’-piperidin];1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[indol-3,4’-piperidin]-2(1H)-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[1,2-benzizotiazol-3,3’-pirolidin]-1,1-dioksid;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’- pirolidin]-3-on;1’-({1-[4-(piridin-2-iloksi)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklobutil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metoksifenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(2,4-dihlorofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin];1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-1H-spiro[furo[3,4-c]piridin-3,3’-pirolidin]-1-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[indol-3,3’-pirolidin]-2(1H)-on;1’-({1-[4-(1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(difluorometoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(6-fenilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(6-fenilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-pirolidin-1-ilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-pirolidin-1-ilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on; i1’-{[1-(6-pirolidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on ilinjihove farmaceutski prihvatljive soli.
20. Jedinjenje iz zahteva 1 izabrano od: 1’-{[1-(6-pirolidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-feniletoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(1-fetilciklopropil)metoksi]fenil}ciklopropil)-karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(2-fluorobenzil)oksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(kinolin-2-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(3-fluorobenzil)oksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1,3-benzotiazol-2-ilmetoksi)fenil]ciklopropil}-karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-{[3,5-bis(trifluorometil)benzil]oksi}fenil)-ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[2-(4-fluorofenil)etoksi]fenil}ciklopropil)-karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-[(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenoksi)metil]benzonitril;1’-{[1-(4-fenoksifenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-4-ilmetoksi)fenil]ciklopropil}-karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-2-ilmetoksi)fenil]ciklopropil}-karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-piridin-4-ilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-ciklopropilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(2-fluoro-4-piridin-2-ilfenil)ciklopropil]-karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(E)-2-(4-metilfenil)vinil]fenil}-ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-piridin-2-iletoksi)fenil]ciklopropil}-karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-piridin-2-iletoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{ 4-[(E)-2-piridin-4-ilvinil]fenil}ciklopropil)-karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(3,5-dimetilizoksazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-metil-1H-pirazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4’-(metilsulfonil)bifenil-4-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(3-metil-1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[3-(trifluorometil)-1H-pirazol-1-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(4-metil-1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2H-indazol-2-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-benzimidazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-metil-1H-imidazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-1,2,4-triazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-Hidroksiciklopentil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-Ciklopentilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1 -[4-(1-Hidroksiciklopentil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-Hidroksiciklobutil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-Hidroksiciklobutil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(tetrahidro-2H-piran-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-ciklobutilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(4-hidroksitetrahidro-2H-piran-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-Hidroksitetrahidro-2H-piran-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-amino-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-metil-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-etil-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-amino-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-metil-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[trans-1-(4-hlorofenil)-3-hidroksiciklobutil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[cis-1-(4-hlorofenil)-3-fluorociklobutil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[cis-1-(4-hlorofenil)-3-fluorociklobytil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin];1’-{[cis-1-(4-hlorofenil)-3-fluorociklobutil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[cis-1-(4-hlorofenil)-3-fluorociklobutil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-hlorofenil)ciklobutil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-({1-[4-(1H-indazol-1-il)fenil]ciklobutil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[3-(trifluorometil)-1H-pirazol-1-il]fenil}ciklobutil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-benzimidazol-1-il)fenil]ciklobutil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklobutil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-piridin-4-ilciklobutil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1{[1-(4-piridin-4-ilfenil)ciklobutil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N,N-dimetil-4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)piridin-2-il]piperazin-1-karboksamid;1’-[(1-{6-[4-(metilsulfonil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[4-(2-fluorofenil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(3,3-difluoropirolidin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on.1’-[(1-{6-[3-Hidroksipirolidin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-{1-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]pirolidin-3-il}acetamid;1’-({1-[6-(1,3-dihidro-2H-izoindol-2-il)piridin-3-il]ciklo-propil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(3,4-dihidro-izokinolin-2(1H)-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(6-morfolin-4-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(4-hidroksipipendin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-{4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]fenilacetamid;1’-({1 -[6-(2-fluorofenil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(1-benzotien-3-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(2,3’-bipiridin-5-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(1-metil-1H-indol-5-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’ -pirolidin]-3-on;1’-[(1-{6-[3-(trifluorometoksi)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(3-tienil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[3-(trifluorometil)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(1-metil-1H-pirazol-4-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(6-hloropiridin-3-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(benziloksi)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-kinolin-3-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(1-metil-1H-pirazol-4-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(benziloksi)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(6-hloropiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(3,4-dihidroizokinolin-2(1H)-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(1,3-dihidro-2H-izoindol-2-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(3,3-difluoropirolidin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Izobutil 4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklopropil}piridin-2-il)piperazin-1-karboksilat;2-[4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklopropil}piridin-2-il)piperazin-1-il]benzonitril;1’-[(1-{6-[4-(4-fluorofenil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{6-[3-(trifluorometil)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{6-[3-(trifluorometoksi)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}piridin-2-il)benzonitril;1’-({1-[6-(3-hloro-4-fluorofenil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{6-[4-(metoksimetil)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3--on;N-[3-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}piridin-2-il)fenil]acetamid; i4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}piridin-2-il)benzamid, ili njihove farmaceutski prihvatljive soli.
21. Jedinjenje iz zahteva 1 izabrano od: 1’-[(1-{6-[4-(metilsulfonil)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(1-metil-1H-indol-5-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(1-benzotien-5-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(6-kinolin-3-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(3-tienil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-okso-2,3-dihidro-1H-indol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(3-metil-2-okso-2,3-dihidro-1H-benzimidazol-1-il)fenil]ciklopropil} karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}benzonitril;4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklopropil} benzenkarbotioamid;1’-[(1-{4-[1-(metilsulfonil)-1,2,3,6-tetrahidropiridin-4-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(E)-2-piridin-4-ilvinil]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[ciklopentil(fluoro)metil]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(tetrahidro-2H-piran-4-iloksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;terc-butil (4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenoksi)acetat;(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklopropil} fenoksi)acetonitril;1’-[(1-{4-[(5-metilizoksazol-3-il)metoksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(ciklopentilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(kinolin-3-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(kinolin-4-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(kinolin-6-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-3-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-(trifluorometil)-1’-({1-[4-(trifluorometil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(trifluorometoksi)fenil]ciklopropil}karbonil)-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2,4-difluorofenil)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(1,3-benzotiazol-2-il)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-fluoro-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-4-fluoro-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;7-fluoro-1’-[(1-{4-[(trifluorometil)tio]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-bromofenil)ciklopropil]karbonil}-7-fluoro-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(1,3-benzotiazol-2-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(1,3-benzotiazol-2-il)ciklopropil]karbonil}-6-hloro-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-({1-[4-(trifluorometoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(2-fluorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(4-hlorofenil)-1,3-tiazol-2-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)benzonitril;1’-{[1-(4-bromofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(pirolidin-1-ilkarbonil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil) benzohidrazid;N-metil-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)benzamid;4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil) benzenkarbotioamid;1’-[(1-{4-[2-(trifluorometil)-1H-imidazol-4-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-metil-1H-pirazol-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on ;N-ciklopropil-4’-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)bifenil-4-karboksamid;1’-[(1-{4-[5-(trifluorometil)-1H-1,2,4-triazol-3-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-tetrazol-5-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-amino-1,3-oksazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-pirimidin-5-ilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(6-fluoropiridin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(6-pirolidin-1-ilpiridin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-ciklopropil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]piridin-2-karboksamid;N-metil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]piridin-2-karboksamid;1’-({1-[4-(metilsulfonil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(trifluorometil)tio]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-hloro-2-fluorofenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksopiridin-1(2H)-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Metil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-carboksilat;1’-[(1-{4-[4-(metilsulfonil)-2-oksopiperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;7-fluoro-1’-[(1-{4-[3-(trifluorometil)-1H-pirazol-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]ciklopropankarboksamid;N-[4-(1-{[3-Okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]benzenesulfonamid;Metil allil[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]karbamat;1’-({1-[4-(1H-1,2,4-triazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-kinolin-6-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-piridin-4-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-kinolin-2-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-piridin-2-ilciklopropil)carboxil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(1,3-benzotiazol-2-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-({1-[4-(pirolidin-1-ilmetil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;6-hloro-1’-({1-[4-(trifluorometil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(3-tienil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(2-naftil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-4-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[izochromene-3,3’-pirolidin]-1(4H)-on;1’-{[1-(2-fluoro-4-piridin-4-ilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;5-metoksi-1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3-okso-3H-spiro[2-benzofuran-1,3’-pirolidin]-5-karbonitril;1’-({1-[3’-(hidroksimetil)bifenil-4-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2’-(metiltio)bifenil-4-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(1,3-benzotiazol-2-il)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(2-naftil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-({1-[4-(difluorometoksi)fenil]ciklopropil}karbonil)-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-{[4-(trifluorometoksi)benzil]oksi}fenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on; i1’-[(1-{4-[1-(4-bromofenil)etoksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on ili njihove farmaceutski prihvatljive soli.
22.Jedinjenje iz zahteva 1 izabrano od: 1’-{[1-(4-piridin-3-ilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirrolidin]-3-on;[4-(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenil)-1,3-tiazol-2-il]acetonitril;1’-({1-[4-(2-piridin-3-il-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-propionil-1,2,3,6-tetrahidropiridin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]-3,6-dihidropiridin-1(2H)-karboksilat;4-[(E)-2-(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenil)vinil]benzonitril;1’-{[1-(2-fluoro-4-piridin-4-ilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{2-fluoro-4-[3-(trifluorometil)-1H-pirazol-1-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2H-indazol-2-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(3,3-difluoropirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-izopropil-2-okso-1,3-oksazolidin-3-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksoimidazolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksoimidazolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-izopropil-2-okso-1,3-oksazolidin-3-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;metil 3-okso-4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]piperazin-1-karboksilat;1’-[(1-{6-[4-(ciklopropilkarbonil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[4-(piridin-4-iloksi)piperidin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[3-(piridin-4-iloksi)pirolidin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(6-metoksipiridin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;[4’-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)bifenil-3-il]acetonitril;1’-({1-[4-(6-aminopiridin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(6-hidroksipiridin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(5-metilpiridin-2-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(piridin-2-iloksi)metil]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(piridin-3-iloksi)metil]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(piridin-4-iloksi)metil]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;3-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)benzonitril;1’-[(1-bifenil-3-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(1-naftil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-kinolin-6-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[(5-metilizoksazol-3-il)metoksi]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-piridin-3-il-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[5-(trifluorometil)-1,3,4-oksadiazol-2-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-terc-butil-1,3-tiazol-2-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-hlorofenil)-1,3-tiazol-2-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’,1"-[1,4-fenilenbis(ciklopropan-1,1-diilkarbonil)]bis(3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on);4-hidroksi-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-metoksi-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-piridin-3-ilciklobutil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklobutil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklobutil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(2,4-dihlorofenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(4-bromofenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(4-metoksifenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(4-fenoksifenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-[(1-{4-[(trifluorometil)tio]fenil}ciklopropil)karbonil]spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(3-bromofenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(3-metoksifenil)ciklopropil]karbonil}spiro[pirido[3,4-d][1,3]oksazin-4,3’-pirolidin]-2(1H)-on;1’-{[1-(6-hloropiridin-3-il)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on; i1’-({1-[4-(trifluorometil)fenil]ciklopropil}karbonil)-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on ili njihova farmaceutski prihvatljiva so.
23.Jedinjenje iz zahteva 1 izabrano od: 1’-{[1-(4-Metoksifenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-({1-[4-(trifluorometoksi)fenil]ciklopropil}karbonil)-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(4-fluorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1 -(2-hloro-4-fluorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(2,4-difluorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(3-hlorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{-(3,4-dihlorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(2,3-difluorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;1’-{[1-(2,4-dihlorofenil)ciklopropil]karbonil}-7H-spiro[furo[3,4-b]piridin-5,3’-pirolidin]-7-on;Etil 4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat;1’-[(1-{6-[4-(etilsulfonil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(4-metilpiperazin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(4-fenilpiperazin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[4-(3-metilbutanoil)piperazin-1-il]piridin-3-il}ciklopropilkarbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{6-[4-(ciklopropilmetil)piperazin-1-il]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[6-(2,5-dihidro-1H-pirol-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(6-piperidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-metil-2-oksopiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-acetil-2-okso-piperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;terc-butil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]piperazin-1-karboksilat;1’-({1-[4-(4-Izobutirilpiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(ciklopropil karbonil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(metilsulfonil)piperazin-1-il]fenil}ciklopropil karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-metilpiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-metil-N-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]ciklopropankarboksamid;N-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil) fenil]acetamid;1’-({1-[4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksopiperidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1-metil-3-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]imidazolidin-2,4-dion;1’-{[1-(4-morfolin-4-ilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-piridin-3-ilciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-metil-4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)piridin-2-il]benzamid;N,N-dimetil-4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)piridin-2-il]benzamid;1’-[(1-{6-[4-(metilsulfonil)fenil]piridin-3-il}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metoksifenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-2-iloksi)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(piridin-3-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(izokinolin-1-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-vinilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;metil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]-3,6-dihidropiridin-1(2H)-karboksilat;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil} ciklopropil)fenil]-3,6-dihidropiridin-1(2H)-karboksilat;1’-({1-[4-(1-acetil-1,2,3,6-tetrahidropiridin-4-il)fenil]ciklopropil}karbonil)-3H-spiro [2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[1-(3-metilbutanoil)-1,2,3,6-tetrahidropiridin-4-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;5-hidroksi-1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-5-ol;1’-({1-[4-(pirolidin-1-ilmetil)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-{[1-(6-pirolidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(4-fenilpiperazin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolid in]-3-on;metil 4-[5-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat ;Etil 4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}piridin-2-il)piperazin-1-karboksilat;Izopropil 4-(5-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}piridin-2-il)piperazin-1-karboksilat;1’-({1-[6-(4-hlorofenil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(4-fluorofenil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(4-fluoro-2-metilfenil)piridin-3-il]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-hloro-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-hidroksi-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-metoksi-1’-[(1-kinolin-4-ilciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(4-fluorobenzil)oksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-{[4-(trifluorometil)benzil]oksi}fenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(2-hloro-4-fluorobenzil)oksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(4-bromo-2-fluorobenzil)oksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;3-fluoro-4-[(4- {1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenoksi)metil]benzonitril;1’-[(1-{4-[1-(2-fluorofenil)etoksi]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;4-[1-(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklo-propil}fenoksi)etil]benzonitril;1’-({1-[4-(kinolin-2-ilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-metoksifenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(4-metoksifenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-metoksifenil)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(ciklopentiloksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(alliloksi)fenil]ciklo-propil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-metoksietoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(ciklopropilmetoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(trifluorometil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-vinilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(E)-2-piridin-2-ilvinil]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-izobutiril-1,2,3,6-tetrahidropiridin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-acetilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Etil 4-(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil] ciklopropil}fenil)piperidin-1-karboksilat;1’-({1-[4-(1-izobutirilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-propionilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[1-(3-metilbutanoil)piperidin-4-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-piriolidin]-3-on;1’-({1-[4-(2-izopropil-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[2-(dimetilamino)-1,3-tiazol-4-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-amino-1,3-tiazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;3-fluoro-4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklo-propil}benzonitril;1’-({1-[2-fluoro-4-(4-metil-1,3-tiazol-2-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on; i1’-[(1-{4-[5-(trifluorometil)-1,3,4-oksadiazol-2-il]fenil}ciklo-propil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on ili njihova farmaceutski prihvatljiva so.
24.Jedinjenje iz zahteva 1 izabrano od: 1’-({1-[4-(3-metilizoksazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-piridin-2-iletil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(3-metil-1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(3-amino-1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1H-benzimidazol-1-il)-2-fluorofenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{2-fluoro-4-[2-(trifluoro-metil)-1H-benzimidazol-1-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-metoksi-1H-benzimidazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Etil 4-(4-{1-[(3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il)karbonil]ciklopropil}fenil)piperazin-1-karboksilat;Izopropil 4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperazin-1-karboksilat;1’-({1-[4-(4-propionilpiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(4-izobutirilpiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(ciklopropil karbonil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro [furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(Metilsulfonil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksopiridin-1(2H)-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Metil [4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]karbamat;N-[4-(1-{[3-Okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]metansulfonamid;1’-{[1-(2-fluorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-hlorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-bromofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[2-(Trifluorometil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-metoksifenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-metilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2,3-difluorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-hloro-6-fluorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(1-naftil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-fluorofenil)ciklopropil]karbonil}-6-(trifluorometil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(4-metilfenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-({1-[4-(trifluoro-metil)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(2,4-difluorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-({1-[3-(difluorometoksi)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2,4-dihlorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-4-metoksi-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklopropil]karbonil}-4-hidroksi-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(3,4-dihlorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hloro-2-fluorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;6-hloro-1’-{[1-(2,4-difluorofenil)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2-hloro-4-fluorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(2,4-difluorofenil)ciklo-propil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(metiltio)fenil]ciklo-propil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[(trifluorometil)tio]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(4-hlorofenil)ciklo-pentil]karbonil}-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Metil 4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat;N,N-dimetil-4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperazin-1-karboksamid;Metil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperazin-1-karboksilat;1’-({1-[2-fluoro-4-(4-propionilpiperazin-1-il)fenil]ciklo-propil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(4-izobutirilpiperazin-1-il)fenil]ciklo-propil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(ciklopropil karbonil)piperazin-1-il]-2-fluoro-fenil}ciklopropil) karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(4-acetilpiperazin-1-il)-2-fluorofenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N,Ndimetilpiperazin-1-karboksamid;1’-({1-[4-(4-hidroksipiperidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N,N-dimetil-1-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperidin-4-karboksamid;Metil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperidin-1-karboksilat;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperidin-1-karboksilat;1’-({1-[4-(1-acetilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-izobutirilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-propionilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[1-(3-metilbutanoil)piperidin-4-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-acetilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-izobutirilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(1-propionilpiperidin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[1-(3-metilbutanoil)piperidin-4-il]fenil}ciklo-propil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Metil 4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperidin-1-karboksilat;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperidin-1-karboksilat;Izopropil-4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperidin-1-karboksilat;Metil 4-hidroksi-4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperidin-1-karboksilat;Etil 4-hidroksi-4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperidin-1-karboksilat;Izopropil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piperazin-1-karboksilat;1’-[(1-{4-[6-(pirolidin-1-ilkarbonil)piridin-3-il]fenil}ciklo-propil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-Etil-N-metil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piridin-2-karboksamid;N,N-dietil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)fenil]piridin-2-karboksamid;terc-butil {4-[5-(-1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]fenil}karbamat;N,N-dimetil-1-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklo-propil)piridin-2-il]piperidin-4-karboksamid; i1’-{[1-(6-piperidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on ili njihove farmaceutski prihvatljive soli.
25.Jedinjenje iz zahteva 1 izabrano od: 1’-({1-[2-fluoro-4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-okso-1,3-oksazolidin-3-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[4-(2-oksoazetidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-oksoazetidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(2-Oksoazetidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2-oksoazetidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;Propil 4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat;Izobutil 4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat;Izopropil 4-[5-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)piridin-2-il]piperazin-1-karboksilat;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;Propil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;Izobutil 4-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;1’-[(1-{4-[4-(ciklopropilacetil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-(4-[4-(ciklopropilacetil)piperazin-1-il]-2-fluorofenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(3-metilbutanoil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{2-fluoro-4-[4-(3-metilbutanoil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro [2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(tetrahidro-2H-piran-4-ilkarbonil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Etil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;Propil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-metilpiperazin-1-karboksamid;1’-({1-[2-fluoro-4-(4-izobutirilpiperazin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(ciklopropilacetil)piperazin-1-il]-2-fluorofenil}ciklopropil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Metil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;Etil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;Propil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;izo-propil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;izo-butil 4-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;1’-[(1-{4-[4-(ciklopropilkarbonil)piperazin-1-il]-2-fluorofenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{2-fluoro-4-[4-(3-metilbutanoil)piperazin-1-il]fenil}ciklopropil)karbonil]-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;N,N-dimetil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid;N-etil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid;N-izopropil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-metilpiridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-etilpiridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-i-propilpiridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N,N-dimetilpiridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-metilpiridin-2-karboksamid;N-etil-5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-izopropilpiridin-2-karboksamid;5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N,N-dimetilpiridin-2-karboksamid;6-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-metilnikotinamid;6-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N,N-dimetilnikotinamid;N-metil-6-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]nikotinamid;N,N-dimetil-6-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]nikotinamid;1’-({1-[4-(1-izobutiril-1,2,3,6-tetrahidropiridin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[4-(1-propionil-1,2,3,6-tetrahidropiridin-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[3-fluoro-4-(3-metil-1H-pirazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-{[1-(6-azetidin-1-ilpiridin-3-il)ciklopropil]karbonil}-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-({1-[6-(2-oksoazetidin-1-il)piridin-3-il]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Metil [3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]karbamat;Metil [3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]karbamat;1’-({1-[4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-3-on;1’-[(1-{4-[4-(ciklopropilkarbonil)piperazin-1-il]fenil}ciklobutil)karbonil]-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;Etil 4-[4-(1-{[3-okso-1’H,3H-spiro[furo[3,4-c]piridin-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piperazin-1-karboksilat;N,N-dietil-5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid;1’-({1-[4-(2-oksopirolidin-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(1H-1,2,3-triazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(2H-1,2,3-triazol-2-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(1H-1,2,4-triazol-1-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;1’-({1-[2-fluoro-4-(4H-1,2,4-triazol-4-il)fenil]ciklopropil}karbonil)-3H-spiro[2-benzofuran-1,3’-pirolidin]-3-on;N-etil-5-[3-fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid i 5-[3-Fluoro-4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]-N-izopropilpiridin-2-karboksamid ili njihove farmaceutski prihvatljive soli.
26. Metod modulisanja aktivnosti 11βHSD1 ili MR ex vivo sadrži pomenute 11βHSD1 ili MR sa jedinjenjima prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli.
27. Pomenuti metod iz zahteva 26 gde se pomenuto modulisanje inhibira.
28. Jedinjenja prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli za upotrebu u proizvodnji medikamenata za lečenje bolesti, pri čemu je spomenuta bolest gojaznost, dijabetes, intolerancija na glukozu, otpornost na insulin, hiperglikemija, hipertenzija, hiperlipidemija, kognitivno oštećenje, demencija, glaukom, kardiovaskularni poremećaji, osteoporoza ili zapaljenje.
29. Jedinjenja prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli za upotrebu u proizvodnji medikamenata za tretman bolesti pri čemu je spomenuta bolest hipertenzija, kardiovaskularna bolest, bolest bubrega, inflamatorne bolesti, otkazivanje srca, ateroskleroza, arteroskleroza, koronarna bolest arterija, tromboza, angina, periferalne vaskularne bolesti, oštećenje vaskularnog zida, moždani udar, dislipidemija, hiperlipoproteinemija, dijabetička dislipidemija, mešana dislipidemija, hiperholesterolemija, hipertrigliceridinemija, dijabetes tip 1, tip 2, gojaznost, metabolički sindrom, otpornost na insulin ili generalno oštećenje organa vezano za aldosteron.
30. Upotreba jedinjenja prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli, u proizvodnji medikamenata za tretman dijabetesa tipa 2.
31. Farmaceutske kompozicije koje sadrže jedinjenja prema bilo kojem od zahteva od 1 do 25 ili njihove farmaceutski prihvatljive soli i farmaceutski prihvatljiv nosač.
32. Jedinjenja prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli za upotrebu u tretmanu bolesti pri čemu je spomenuta bolest gojaznost, dijabetes, intolerancija na glukozu, otpornost na insulin, hiperglikemija, hipertenzija, hiperlipidemija, kognitivno oštećenje, demencija, glaukom, kardiovaskularni poremećaji, osteoporoza ili zapaljenje.
33. Jedinjenja prema bilo kom zahtevu od 1 do 25 ili njihove farmaceutski prihvatljive soli, za upotrebu u tretmanu bolesti, pri čemu je spomenuta bolest hipertenzija, kardiovaskularne bolesti, bolesti bubrega, inflamatorne bolesti, otkazivanje srca, ateroskleroza, arteroskleroza, koronarna bolest arterija, tromboza, angina, periferalne vaskularne bolesti, oštećenje vaskularnog zida, moždani udar, dislipidemija, hiperlipoproteinemija, dijabetička dislipidemija, mešana dislipidemija, hiperholesterolemija, hipertrigliceridinemija, dijabetes tip 1, tip 2, gojaznost, metabolički sindrom, otpornost na insulin ili generalno oštećenje organa vezano za aldosteron.
34. Jedinjenje prema bilo kom zahtevu od 1 do 25 ili njegova farmaceutski prihvatljiva so za upotrebu u tretmanu dijabetesa tipa 2.
35. Jedinjenje koje je N-metil-5-[4-(1-{[3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid ili njegova farmaceutski prihvatljiva so.
36. Jedinjenje koje je N-metil-5-[4-(1-{[(1R)-3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil)fenil]piridin-2-karboksamid ili njegova farmaceutski prihvatljiva so.
37. Jedinjenje koje je N-metil-5-[4-(1-{[(1R)-3-okso-1’H,3H-spiro[2-benzofuran-1,3’-pirolidin]-1’-il]karbonil}ciklopropil) fenil]piridin-2-karboksamid.
38. Farmaceutskakompozicija sadrži jedinjenja prema zahtevu 35 ili 36 ili njihove farmaceutski prihvatljive soli ili jedinjenje prema zahtevu 37, kao i farmaceutski prihvatljiv nosač.
39. Upotreba jedinjenja prema zahtevu 35 ili 36 ili njihove farmaceutski prihvatljive soli, ili jedinjenje prema zahtevu 37, u proizvodnji medikamenata za tretman pacijenata izabranih sa bolestima kao što su gojaznost, dijabetes, intolerancija na glukozu, otpornost na insulin, hiperglikemija, hipertenzija, hiperlipidemija, kognitivno oštećenje, demencija, glaukom, kardiovaskularni poremećaji, osteoporoza ili zapaljenje.
40. Upotreba jedinjenja prema zahtevu 35 ili 36 ili njihova farmaceutski prihvatljiva so, ili jedinjenje prema zahtevu 37, u proizvodnji medikamenta za tretman dijabetesa tipa 2.
41. Jedinjenje prema zahtevu 35 ili 36 ili njihove farmaceutski prihvatljive soli, ili jedinjenje prema zahtevu 37, za upotrebu u tretmanu pacijenata sa bolestima izabranim od gojaznosti, dijabetesa, intolerancije na glukozu, otpornosti na insulin, hiperglikemiju, hipertenzije, hiperlipidemije, kognitivnog oštećenja, demencije, glaukoma, kardiovaskularnih poremećaja, osteoporoze, i zapaljenja.
42. Jedinjenje prema zahtevu 35 ili 36 ili njihova farmaceutski prihvatljiva so, ili jedinjenje prema zahtevu 37, za upotrebu u tretmanu dijabetesa tipa 2.
MEP-2015-166A 2004-05-07 2005-05-04 Amido jedinjenja i njihova upotreba kao farmaceutckih proizvoda ME02231B (me)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US56927304P 2004-05-07 2004-05-07
US60205104P 2004-08-17 2004-08-17
US60279104P 2004-08-19 2004-08-19
US63880304P 2004-12-22 2004-12-22
PCT/US2005/015559 WO2005110992A1 (en) 2004-05-07 2005-05-04 Amido compounds and their use as pharmaceuticals
EP05745656.8A EP1756063B1 (en) 2004-05-07 2005-05-04 Amido compounds and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
ME02231B true ME02231B (me) 2016-02-20

Family

ID=35394113

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-166A ME02231B (me) 2004-05-07 2005-05-04 Amido jedinjenja i njihova upotreba kao farmaceutckih proizvoda

Country Status (29)

Country Link
US (7) US7304081B2 (me)
EP (2) EP1756063B1 (me)
JP (2) JP5265913B2 (me)
KR (1) KR101252227B1 (me)
AU (1) AU2005243222C1 (me)
BR (1) BRPI0510736B1 (me)
CA (1) CA2565238C (me)
CR (1) CR8702A (me)
CY (1) CY1116779T1 (me)
DK (1) DK1756063T3 (me)
EA (1) EA025359B1 (me)
EC (1) ECSP066978A (me)
ES (1) ES2550006T3 (me)
GE (1) GEP201706611B (me)
HK (1) HK1218545A1 (me)
HR (1) HRP20151064T1 (me)
HU (1) HUE025521T2 (me)
IL (1) IL179042A (me)
ME (1) ME02231B (me)
MX (1) MX340538B (me)
NO (1) NO340031B1 (me)
NZ (1) NZ550775A (me)
PL (1) PL1756063T3 (me)
PT (1) PT1756063E (me)
RS (1) RS54236B1 (me)
SG (1) SG151329A1 (me)
SI (1) SI1756063T1 (me)
TW (1) TWI350168B (me)
WO (1) WO2005110992A1 (me)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
US20050288317A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8071624B2 (en) * 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
JP2008504278A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
JP2008504280A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
KR101257233B1 (ko) * 2004-07-29 2013-04-29 아더시스 인코포레이티드 세로토닌 수용체 조절제로서의 트리사이클릭 인데노-피롤유도체
WO2006020598A2 (en) * 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8110581B2 (en) 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
CA2585797C (en) * 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
CN101103016A (zh) * 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
SG176463A1 (en) 2005-02-22 2011-12-29 Univ Michigan Small molecule inhibitors of mdm2 and uses thereof
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
US20090291988A1 (en) * 2005-06-14 2009-11-26 Renata Oballa Reversible Inhibitors of Monoamine Oxidase A and B
CA2621255A1 (en) * 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
WO2007067504A2 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
AU2007207055B2 (en) 2006-01-18 2011-06-02 F. Hoffmann-La Roche Ag Thiazoles as 11 beta-HSD1 inhibitors
TW200804341A (en) * 2006-01-31 2008-01-16 Incyte Corp Amido compounds and their use as pharmaceuticals
EP1981848A2 (en) 2006-02-07 2008-10-22 Wyeth 11-beta hsd1 inhibitors
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) * 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2018378A2 (en) 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
EP2061791A1 (en) * 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
AU2007294771A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
JP2010503676A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療
CN103271906A (zh) 2006-10-12 2013-09-04 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
US20080306102A1 (en) * 2007-05-18 2008-12-11 Kowa Co., Ltd. Novel spirooxyindole compounds and drugs containing same
ATE508110T1 (de) * 2007-06-05 2011-05-15 Nsab Af Neurosearch Sweden Ab Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
WO2010023931A1 (ja) 2008-08-29 2010-03-04 興和株式会社 １－アダマンチルアゼチジン－２－オン誘導体及びこれを含有する医薬
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (zh) 2008-10-17 2017-04-19 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
TW201022210A (en) 2008-10-29 2010-06-16 Kowa Co 1,2-diazetidin-3-one derivatives and drugs containing same
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
JP5609150B2 (ja) * 2009-02-27 2014-10-22 アステラス製薬株式会社 ピペリジン誘導体
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US8445696B2 (en) 2009-10-14 2013-05-21 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
JP2013510860A (ja) 2009-11-12 2013-03-28 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
WO2011140425A1 (en) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
WO2012039448A1 (ja) * 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺－吲哚酮ｍｄｍ２拮抗劑
TW201604196A (zh) 2011-02-02 2016-02-01 維泰克斯製藥公司 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
EP2686325B1 (en) 2011-03-14 2016-12-14 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
SG194873A1 (en) 2011-05-11 2013-12-30 Sanofi Sa Spiro-oxindole mdm2 antagonists
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
JP6050238B2 (ja) * 2011-10-19 2016-12-21 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
KR102712879B1 (ko) 2012-07-13 2024-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
EP3134408B1 (en) 2014-04-22 2020-08-12 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017074833A1 (en) * 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2020048830A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
TW202024083A (zh) 2018-09-03 2020-07-01 德商拜耳廠股份有限公司 3,9-二氮雜螺[5.5]十一烷化合物
CN110305141B (zh) * 2019-07-18 2022-01-11 深圳市三启药物开发有限公司 一种螺(3,3’-异丙基吡咯烷氧化吲哚)类肝x受体调节剂及其制备方法和应用
EP4308125A4 (en) * 2021-03-18 2025-03-12 Merck Sharp & Dohme LLC Plasmakallikrein Inhibitors
US20240208994A1 (en) * 2021-04-22 2024-06-27 Merck Sharp & Dohme Llc Plasma kallikrein inhibitors
JP2025503737A (ja) 2022-01-18 2025-02-04 メイズ セラピューティクス， インコーポレイテッド Ａｐｏｌ１阻害剤及び使用方法
WO2025015104A2 (en) * 2023-07-11 2025-01-16 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
TW202517642A (zh) * 2023-07-11 2025-05-01 美商梅斯治療股份有限公司 Ａｐｏｌ１抑制劑及其使用方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262366A (me) * 1960-03-14
US3201466A (en) * 1963-03-08 1965-08-17 Gulf Oil Corp Substituted cyclopropanecarboxanilide herbicides
DE2114420A1 (de) * 1971-03-25 1972-10-05 Merck Patent Gmbh, 6100 Darmstadt Substituierte Phenylalkanol-Derivate und Verfahren zu ihrer Herstellung
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
US3933829A (en) * 1974-08-22 1976-01-20 John Wyeth & Brother Limited 4-Aminoquinoline derivatives
TR18917A (tr) * 1974-10-31 1977-12-09 Ciba Geigy Ag 1-(bis-triflormetilfenil)-2-oksopirolidin-4-karbonik asitleri ve bunlarin tuerevleri
FR2312247A1 (fr) 1975-05-30 1976-12-24 Parcor Derives de la thieno-pyridine, leur procede de preparation et leurs applications
US4145435A (en) * 1976-11-12 1979-03-20 The Upjohn Company 2-aminocycloaliphatic amide compounds
GB2068961B (en) * 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
JPS57156450A (en) * 1981-03-24 1982-09-27 Ihara Chem Ind Co Ltd 1-(4-chlorophenyl)-1-cyclopentanecarboxylic acid derivative, its preparation, and aquatic life repellent containing said compound as active component
US4439606A (en) 1982-05-06 1984-03-27 American Cyanamid Company Antiatherosclerotic 1-piperazinecarbonyl compounds
EP0273659A1 (en) 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiro compounds, their production and use
US5206240A (en) 1989-12-08 1993-04-27 Merck & Co., Inc. Nitrogen-containing spirocycles
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
JPH04334357A (ja) 1991-05-02 1992-11-20 Fujirebio Inc 酵素阻害作用を有するアシル誘導体
DE4234295A1 (de) 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW239211B (en) * 1993-04-02 1995-01-21 Hyundai Electronics America Electromagnetic lens actuator for optical disk drive
FR2705343B1 (fr) 1993-05-17 1995-07-21 Fournier Ind & Sante Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique.
FR2724656B1 (fr) 1994-09-15 1996-12-13 Adir Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2736053B1 (fr) 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines
GB9517622D0 (en) * 1995-08-29 1995-11-01 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
EP1090012A4 (en) 1998-07-02 2005-04-06 Merck & Co Inc INHIBITORS OF PRENYL-PROTEIN TRANSFERASE
TWI248435B (en) 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
EP1165500A1 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase
IT1313552B1 (it) 1999-06-29 2002-09-09 European Molecular Biology Lab Embl Isoforme del recettore alfa degli estrogeni umano
US6659293B1 (en) 1999-07-07 2003-12-09 Odwalla, Inc. Pull-out shelf stocking system
BR0012590A (pt) 1999-07-21 2002-04-09 Astrazeneca Ab Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central
WO2001010823A1 (de) 1999-08-07 2001-02-15 Boehringer Ingelheim Pharma Kg Carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
WO2001030780A2 (en) 1999-10-27 2001-05-03 Cor Therapeutics, Inc. Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
US6496627B1 (en) 2000-07-14 2002-12-17 Tyco Telecommunications (Us) Inc. Device and method for improved long term signal attenuation performance of fiber optic cable and apparatus interfaces
CA2422055A1 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission)
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
WO2002069973A1 (en) * 2001-03-02 2002-09-12 Sepracor, Inc. Piperidine-piperazine ligand for neurotransmitter receptors
WO2003000657A1 (en) * 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US6547958B1 (en) * 2001-07-13 2003-04-15 Chevron U.S.A. Inc. Hydrocarbon conversion using zeolite SSZ-59
WO2003006364A2 (en) * 2001-07-13 2003-01-23 Chevron U.S.A. Inc. Zeolite ssz-59
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003037271A2 (en) 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
US6649606B1 (en) * 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7074788B2 (en) * 2001-11-22 2006-07-11 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
WO2003049736A1 (en) 2001-12-11 2003-06-19 Sepracor, Inc. 4-substituted piperidines, and methods of use thereof
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
JP2003231633A (ja) 2002-02-06 2003-08-19 Tanabe Seiyaku Co Ltd 医薬組成物
US6818772B2 (en) 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
WO2004018479A1 (en) 2002-08-21 2004-03-04 Astrazeneca Ab Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone
TW200413351A (en) 2002-08-21 2004-08-01 Astrazeneca Ab Chemical compounds
AU2003263323A1 (en) 2002-09-07 2004-03-29 Celltech R And D Limited Quinazolinone derivatives
WO2004024065A2 (en) 2002-09-12 2004-03-25 Merck & Co., Inc. Substituted bicyclic thiophene derivatives, compostions containing such compounds and methods of use
MXPA05003632A (es) * 2002-10-11 2005-06-03 Astrazeneca Ab Derivados de piperidina 1, 4-disustituidos y su uso como inhibidores de 11-beta-hidroesteroide deshidrogenasa humana de tipo 1 (11betahsd1).
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US20040188324A1 (en) * 2003-03-26 2004-09-30 Saleh Elomari Hydrocarbon conversion using molecular sieve SSZ-65
WO2004094347A2 (en) 2003-03-26 2004-11-04 Chevron U.S.A. Inc. Molecular sieve ssz-65
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
GEP20084393B (en) 2003-04-24 2008-06-10 Incyte Corp Aza spiro alkane derivatives as inhibitors of metalloproteases
SE0302755D0 (sv) 2003-10-17 2003-10-17 Astrazeneca Ab Novel compounds
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
JP2007514731A (ja) 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための１１−ベータ−ヒドロキシステロイドデヒドロゲナーゼ１型（１１−β−ｈｓｄ−１）の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−２−イル誘導体及び関連化合物
SE0303541D0 (sv) 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP2007536369A (ja) 2004-05-06 2007-12-13 ファイザー・インク プロリン及びモルホリン誘導体の新規化合物
TWI350168B (en) * 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
CA2589565A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
JP2008504278A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
US20050288317A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
US20050288338A1 (en) * 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2006020598A2 (en) 2004-08-10 2006-02-23 Incyte Corporation Amido compounds and their use as pharmaceuticals
MX2007004799A (es) 2004-10-22 2007-06-25 Cargill Inc Proceso para la produccion de maltodextrinas y maltodextrinas.
CA2585797C (en) 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
AU2006203918B2 (en) 2005-01-05 2011-05-19 Abbvie Inc. Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
BRPI0609062A2 (pt) 2005-03-03 2010-02-17 F. Hofmann-La Roche Ag composição farmacêutica, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróide-11ß e utilização dos compostos
CA2621255A1 (en) 2005-09-21 2007-04-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2007067504A2 (en) * 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
TW200804341A (en) * 2006-01-31 2008-01-16 Incyte Corp Amido compounds and their use as pharmaceuticals
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP2013163A1 (en) * 2006-05-01 2009-01-14 Incyte Corporation Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1
EP2018378A2 (en) * 2006-05-17 2009-01-28 Incyte Corporation Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same
CL2008001839A1 (es) * 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
US20050282858A1 (en) 2005-12-22
CR8702A (es) 2009-01-09
US20080255154A1 (en) 2008-10-16
JP5265913B2 (ja) 2013-08-14
AU2005243222B2 (en) 2012-05-03
NO20065442L (no) 2006-11-27
SG151329A1 (en) 2009-04-30
HK1101397A1 (en) 2007-10-18
RS54236B1 (sr) 2015-12-31
PL1756063T3 (pl) 2015-12-31
WO2005110992A1 (en) 2005-11-24
KR101252227B1 (ko) 2013-04-05
MXPA06012894A (es) 2007-02-15
US7304081B2 (en) 2007-12-04
US20150329561A1 (en) 2015-11-19
US8058288B2 (en) 2011-11-15
US9126927B2 (en) 2015-09-08
EP1756063A4 (en) 2009-03-25
GEP201706611B (en) 2017-02-10
ES2550006T3 (es) 2015-11-03
ECSP066978A (es) 2006-12-29
JP2013151519A (ja) 2013-08-08
PT1756063E (pt) 2015-09-15
CA2565238C (en) 2014-08-05
US7776874B2 (en) 2010-08-17
IL179042A (en) 2013-10-31
US20170334847A1 (en) 2017-11-23
CA2565238A1 (en) 2005-11-24
EA200602062A1 (ru) 2007-04-27
JP2007536252A (ja) 2007-12-13
US9957229B2 (en) 2018-05-01
US20100256114A1 (en) 2010-10-07
HUE025521T2 (en) 2016-02-29
BRPI0510736B1 (pt) 2021-06-01
CY1116779T1 (el) 2018-01-10
KR20070007184A (ko) 2007-01-12
NZ550775A (en) 2009-11-27
HK1218545A1 (en) 2017-03-31
NO340031B1 (no) 2017-02-27
US20070179142A1 (en) 2007-08-02
EP1756063A1 (en) 2007-02-28
AU2005243222C1 (en) 2012-12-13
EP1756063B1 (en) 2015-07-08
TW200539858A (en) 2005-12-16
US9670154B2 (en) 2017-06-06
AU2005243222A1 (en) 2005-11-24
HRP20151064T1 (hr) 2015-11-06
MX340538B (es) 2016-07-13
EP2963021A1 (en) 2016-01-06
BRPI0510736A (pt) 2007-11-06
DK1756063T3 (en) 2015-07-20
TWI350168B (en) 2011-10-11
IL179042A0 (en) 2007-03-08
US20120015928A1 (en) 2012-01-19
SI1756063T1 (sl) 2015-12-31
EA025359B1 (ru) 2016-12-30

Similar Documents

Publication Publication Date Title
ME02231B (me) Amido jedinjenja i njihova upotreba kao farmaceutckih proizvoda
JP2007536252A5 (me)
US7074801B1 (en) Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
ES2260277T3 (es) Compuestos de urea y sus procedimientos de utilizacion.
KR102038462B1 (ko) Pi3k의 활성 또는 기능의 억제제의 용도
JP4958772B2 (ja) 脈管形成に関連する高増殖性疾患および疾患を処置するために有用なピロロトリアジン誘導体
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2011518836A5 (me)
JP2018500376A5 (me)
JP2005526029A (ja) 細胞増殖が関与する疾患を治療するためのキノリノン誘導体
RU2016141646A (ru) Ингибиторы trka киназы, основанные на них композиции и способы
JP2016523911A5 (me)
RU2005127335A (ru) Новые производные цикломочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
IL295076B1 (en) Piperidinone derivatives as MDM2 inhibitors for cancer treatment
JP2004531473A (ja) Ｎ−ピリジルカルボキサミド誘導体及びそれらを含有する医薬組成物
JP2010100642A (ja) キナゾリン化合物
JPWO2020231806A5 (me)
JP2011503166A5 (me)
TW201326153A (zh) 磷酸二酯酶第１０ａ型之新穎抑制劑化合物
CA2664810A1 (en) Substituted sulfonamide derivatives
KR20140014173A (ko) 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체
AU2009275654A1 (en) 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as Smo antagonists
EA002851B1 (ru) Хинолиновые и хиназолиновые соединения, применяемые в терапии, особенно при лечении доброкачественной гиперплазии простаты
RU2015144386A (ru) Циклоалкилнитрилпиразолопиридоны в качестве ингибиторов янус-киназы
CA2515790A1 (en) Heterocyclic kinase inhibitors